BrightPath Biotherapeutics Co., Ltd

Business Details

A drug discovery venture developing multiple cell therapy and antibody drug pipelines in parallel. The company handles everything from exploratory research to early-stage clinical trials, generating revenue through upfront licensing fees, milestone payments, and sales royalties from licensing out to domestic and overseas pharmaceutical companies. Its core technology is iPS cell-derived NKT cell therapy, for which it holds an exclusive license from RIKEN. Revenue is nearly zero, with a structure in which R&D expenses directly determine profit and loss.

Recent Overview

Raised ¥2,737 million through exercise of stock acquisition rights, significantly increasing cash balance; BP2202's US IND application enters final stage

Net loss for the full year FY2026 (ending March 2026) was ¥1,305 million (an increase of ¥153 million year-on-year). Through the exercise of the 17th through 20th stock acquisition rights, 48,400,000 shares of common stock were issued for a total of ¥2,747 million, expanding the cash balance at period-end to ¥2,156 million (an increase of ¥1,346 million from the prior period-end). The number of shares outstanding reached 138,891,300 (an increase of approximately 53.5% from the prior period-end). BP2202 has entered the final stage of its IND application to the FDA, with US clinical trials planned to begin in fiscal 2026. An impairment loss of ¥8,807 thousand was recorded due to a change in the estimate of asset retirement obligations. There is no note regarding going concern assumptions. The operating loss forecast for FY2027 (ending March 2027) is ¥1,965 million, indicating an expected widening of losses.

Key Products

Growth Drivers

• Progress on development milestones as BP2202 reaches the final stage of its FDA IND application, with US clinical trials planned to begin in fiscal 2026
• Preferential development treatment (fee waivers, priority review, etc.) resulting from BP2202's FDA orphan drug designation (obtained July 2025)
• Scientific validation of the iPS-NKT technology through publication of BP2201 Phase I clinical trial results in Nature Communications (December 2025)
• Establishment of a scalable manufacturing platform using 3D bioreactors following completion of manufacturing process transfer to Cellistic
• Creation of an advanced genetically engineered CAR-ipsNKT cell therapy program for diverse indications, including solid tumors, utilizing STAR-CRISPR™ gene editing technology
• Continuous fundraising through exercise of stock acquisition rights (¥2,737 million raised in FY2026 (ending March 2026)) and securing a period-end cash balance of ¥2,156 million
• Barrier to entry created by holding exclusive rights to use RIKEN's iPS-NKT allogeneic cell therapy patents (registered in Japan, the US, and Europe)

Risks

• Risk of capital depletion if licensing-out targets continue to go unmet, given the structure in which revenue is nearly zero and R&D expenses directly determine profit and loss (projected operating loss of ¥1,965 million for FY2027 (ending March 2027))
• Risk of delay or rejection of BP2202's US IND application, and risk of development discontinuation due to failure to achieve safety or efficacy in clinical trials
• Risk of share dilution from continued exercise of stock acquisition rights (138,891,300 shares outstanding at end of FY2026 (ending March 2026), an increase of approximately 53.5% from the prior period-end)
• Intensifying competition for licensing-out deals due to competitors (major pharmaceutical companies and biotech ventures) advancing CAR-T and CAR-NK cell therapy development ahead of the company
• Risk of difficulty in raising additional capital due to deteriorating fundraising conditions surrounding biotechnology companies (domestic and overseas interest rate trends, changes in investor risk appetite)
• Foreign exchange risk (a foreign exchange loss of ¥6,679 thousand was recorded during the period) and risk of increased costs from overseas clinical trials